Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)
Summary The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs present...
Gespeichert in:
| Veröffentlicht in: | Epilepsia (Copenhagen) 2017-02, Vol.58 (2), p.181-221 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 221 |
|---|---|
| container_issue | 2 |
| container_start_page | 181 |
| container_title | Epilepsia (Copenhagen) |
| container_volume | 58 |
| creator | Bialer, Meir Johannessen, Svein I. Levy, René H. Perucca, Emilio Tomson, Torbjörn White, H. Steve |
| description | Summary
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I–III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2‐deoxy‐d‐glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE‐217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec‐butylpropylacetamide, FV‐082, 1OP‐2198, NAX 810‐2, and SAGE‐689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes. |
| doi_str_mv | 10.1111/epi.13634 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_499599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1861594776</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3414-2a8ba6cfb468555f5083808637f9fc9d973fc0d18a019881023bfe26054867b93</originalsourceid><addsrcrecordid>eNp1kctu1DAUhi1ERYfCghdAlti0i7R2HN_YjaYDRBqVLgaJnZXLcSclEwc7YdR34KFxyFCpSPXG1tHnT-ecH6F3lFzSeK6gby4pEyx7gRaUpyqhVMiXaEEIZYnmipyi1yHcE0KkkOwVOk1V_CYzvUC_b7278xAC9tA7P2DX4Q4OuOiGJmpb6IemwrUf78JHvMRh3O8L_4CdxcMO8HbX-AGgG3Z43bTFgFeus-Chq2AS3UTR8onoehJFeY2v4VdTQcDn63yz3OLveZ5fvEEntmgDvD3eZ-jbp_V29SXZfP2cr5abpGIZzZK0UGUhKltmQnHOLSeKKaIEk1bbStdaMluRmqqCUK0UJSkrLaSC8EwJWWp2hpLZGw7Qj6XpfTNNZVzRmGPpR3yBybTmeuLPZ7737ucIYTD7JlTQtkUHbgyGKkG5zqQUEf3wH3rvRt_FaSYqI2nKmYzUxUxV3oXgwT62QImZIjVxZeZvpJF9fzSO5R7qR_JfhhG4moFD3PLD8yazvs1n5R_naame</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1864022537</pqid></control><display><type>article</type><title>Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Bialer, Meir ; Johannessen, Svein I. ; Levy, René H. ; Perucca, Emilio ; Tomson, Torbjörn ; White, H. Steve</creator><creatorcontrib>Bialer, Meir ; Johannessen, Svein I. ; Levy, René H. ; Perucca, Emilio ; Tomson, Torbjörn ; White, H. Steve</creatorcontrib><description>Summary
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I–III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2‐deoxy‐d‐glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE‐217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec‐butylpropylacetamide, FV‐082, 1OP‐2198, NAX 810‐2, and SAGE‐689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.</description><identifier>ISSN: 0013-9580</identifier><identifier>EISSN: 1528-1167</identifier><identifier>DOI: 10.1111/epi.13634</identifier><identifier>PMID: 28111749</identifier><identifier>CODEN: EPILAK</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animals ; Anticonvulsants - therapeutic use ; Antiepileptic drugs ; Clinical Trials as Topic ; Congresses as Topic ; Convulsions & seizures ; Drug development ; Drug Discovery ; Drugs, Investigational - pharmacology ; Drugs, Investigational - therapeutic use ; Epilepsy ; Epilepsy - drug therapy ; Epilepsy targets ; Humans ; Prescription drugs ; Progress reports ; Research Report</subject><ispartof>Epilepsia (Copenhagen), 2017-02, Vol.58 (2), p.181-221</ispartof><rights>Wiley Periodicals, Inc. © 2017 International League Against Epilepsy</rights><rights>Wiley Periodicals, Inc. © 2017 International League Against Epilepsy.</rights><rights>Copyright © 2017 International League Against Epilepsy</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3414-2a8ba6cfb468555f5083808637f9fc9d973fc0d18a019881023bfe26054867b93</citedby><cites>FETCH-LOGICAL-c3414-2a8ba6cfb468555f5083808637f9fc9d973fc0d18a019881023bfe26054867b93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fepi.13634$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fepi.13634$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28111749$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:135405101$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Bialer, Meir</creatorcontrib><creatorcontrib>Johannessen, Svein I.</creatorcontrib><creatorcontrib>Levy, René H.</creatorcontrib><creatorcontrib>Perucca, Emilio</creatorcontrib><creatorcontrib>Tomson, Torbjörn</creatorcontrib><creatorcontrib>White, H. Steve</creatorcontrib><title>Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)</title><title>Epilepsia (Copenhagen)</title><addtitle>Epilepsia</addtitle><description>Summary
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I–III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2‐deoxy‐d‐glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE‐217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec‐butylpropylacetamide, FV‐082, 1OP‐2198, NAX 810‐2, and SAGE‐689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.</description><subject>Animals</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Antiepileptic drugs</subject><subject>Clinical Trials as Topic</subject><subject>Congresses as Topic</subject><subject>Convulsions & seizures</subject><subject>Drug development</subject><subject>Drug Discovery</subject><subject>Drugs, Investigational - pharmacology</subject><subject>Drugs, Investigational - therapeutic use</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy targets</subject><subject>Humans</subject><subject>Prescription drugs</subject><subject>Progress reports</subject><subject>Research Report</subject><issn>0013-9580</issn><issn>1528-1167</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctu1DAUhi1ERYfCghdAlti0i7R2HN_YjaYDRBqVLgaJnZXLcSclEwc7YdR34KFxyFCpSPXG1tHnT-ecH6F3lFzSeK6gby4pEyx7gRaUpyqhVMiXaEEIZYnmipyi1yHcE0KkkOwVOk1V_CYzvUC_b7278xAC9tA7P2DX4Q4OuOiGJmpb6IemwrUf78JHvMRh3O8L_4CdxcMO8HbX-AGgG3Z43bTFgFeus-Chq2AS3UTR8onoehJFeY2v4VdTQcDn63yz3OLveZ5fvEEntmgDvD3eZ-jbp_V29SXZfP2cr5abpGIZzZK0UGUhKltmQnHOLSeKKaIEk1bbStdaMluRmqqCUK0UJSkrLaSC8EwJWWp2hpLZGw7Qj6XpfTNNZVzRmGPpR3yBybTmeuLPZ7737ucIYTD7JlTQtkUHbgyGKkG5zqQUEf3wH3rvRt_FaSYqI2nKmYzUxUxV3oXgwT62QImZIjVxZeZvpJF9fzSO5R7qR_JfhhG4moFD3PLD8yazvs1n5R_naame</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Bialer, Meir</creator><creator>Johannessen, Svein I.</creator><creator>Levy, René H.</creator><creator>Perucca, Emilio</creator><creator>Tomson, Torbjörn</creator><creator>White, H. Steve</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>201702</creationdate><title>Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)</title><author>Bialer, Meir ; Johannessen, Svein I. ; Levy, René H. ; Perucca, Emilio ; Tomson, Torbjörn ; White, H. Steve</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3414-2a8ba6cfb468555f5083808637f9fc9d973fc0d18a019881023bfe26054867b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Antiepileptic drugs</topic><topic>Clinical Trials as Topic</topic><topic>Congresses as Topic</topic><topic>Convulsions & seizures</topic><topic>Drug development</topic><topic>Drug Discovery</topic><topic>Drugs, Investigational - pharmacology</topic><topic>Drugs, Investigational - therapeutic use</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy targets</topic><topic>Humans</topic><topic>Prescription drugs</topic><topic>Progress reports</topic><topic>Research Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bialer, Meir</creatorcontrib><creatorcontrib>Johannessen, Svein I.</creatorcontrib><creatorcontrib>Levy, René H.</creatorcontrib><creatorcontrib>Perucca, Emilio</creatorcontrib><creatorcontrib>Tomson, Torbjörn</creatorcontrib><creatorcontrib>White, H. Steve</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Epilepsia (Copenhagen)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bialer, Meir</au><au>Johannessen, Svein I.</au><au>Levy, René H.</au><au>Perucca, Emilio</au><au>Tomson, Torbjörn</au><au>White, H. Steve</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII)</atitle><jtitle>Epilepsia (Copenhagen)</jtitle><addtitle>Epilepsia</addtitle><date>2017-02</date><risdate>2017</risdate><volume>58</volume><issue>2</issue><spage>181</spage><epage>221</epage><pages>181-221</pages><issn>0013-9580</issn><eissn>1528-1167</eissn><coden>EPILAK</coden><abstract>Summary
The Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) took place in Madrid, Spain, on June 26–29, 2016, and was attended by >200 delegates from 31 countries. The present Progress Report provides an update on experimental and clinical results for drugs presented at the Conference. Compounds for which summary data are presented include an AED approved in 2016 (brivaracetam), 12 drugs in phase I–III clinical development (adenosine, allopregnanolone, bumetanide, cannabidiol, cannabidivarin, 2‐deoxy‐d‐glucose, everolimus, fenfluramine, huperzine A, minocycline, SAGE‐217, and valnoctamide) and 6 compounds or classes of compounds for which only preclinical data are available (bumetanide derivatives, sec‐butylpropylacetamide, FV‐082, 1OP‐2198, NAX 810‐2, and SAGE‐689). Overall, the results presented at the Conference show that considerable efforts are ongoing into discovery and development of AEDs with potentially improved therapeutic profiles compared with existing agents. Many of the drugs discussed in this report show innovative mechanisms of action and many have shown promising results in patients with pharmacoresistant epilepsies, including previously neglected rare and severe epilepsy syndromes.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28111749</pmid><doi>10.1111/epi.13634</doi><tpages>41</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0013-9580 |
| ispartof | Epilepsia (Copenhagen), 2017-02, Vol.58 (2), p.181-221 |
| issn | 0013-9580 1528-1167 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_499599 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animals Anticonvulsants - therapeutic use Antiepileptic drugs Clinical Trials as Topic Congresses as Topic Convulsions & seizures Drug development Drug Discovery Drugs, Investigational - pharmacology Drugs, Investigational - therapeutic use Epilepsy Epilepsy - drug therapy Epilepsy targets Humans Prescription drugs Progress reports Research Report |
| title | Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T04%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progress%20report%20on%20new%20antiepileptic%20drugs:%20A%20summary%20of%20the%20Thirteenth%20Eilat%20Conference%20on%20New%20Antiepileptic%20Drugs%20and%20Devices%20(EILAT%20XIII)&rft.jtitle=Epilepsia%20(Copenhagen)&rft.au=Bialer,%20Meir&rft.date=2017-02&rft.volume=58&rft.issue=2&rft.spage=181&rft.epage=221&rft.pages=181-221&rft.issn=0013-9580&rft.eissn=1528-1167&rft.coden=EPILAK&rft_id=info:doi/10.1111/epi.13634&rft_dat=%3Cproquest_swepu%3E1861594776%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1864022537&rft_id=info:pmid/28111749&rfr_iscdi=true |